Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
Ying‐Nai Wang, Heng‐Huan Lee, Jennifer L. Hsu, et al.
Journal of Biomedical Science (2020) Vol. 27, Iss. 1
Open Access | Times Cited: 135

Showing 1-25 of 135 citing articles:

Advances in understanding N-glycosylation structure, function, and regulation in health and disease
Sally Esmail, Morris F. Manolson
European Journal of Cell Biology (2021) Vol. 100, Iss. 7-8, pp. 151186-151186
Open Access | Times Cited: 151
D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1
Ruonan Zhang, Yajing Yang, Wenjing Dong, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 8
Open Access | Times Cited: 147
Molecularly imprinted polymers (MIPs): emerging biomaterials for cancer theragnostic applications
Min Seok Kang, Euni Cho, Hye Eun Choi, et al.
Biomaterials Research (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 46
Advances and prospects of biomarkers for immune checkpoint inhibitors
Hirohito Yamaguchi, Jung-Mao Hsu, Linlin Sun, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 7, pp. 101621-101621
Open Access | Times Cited: 26
Decoding the glycoproteome: a new frontier for biomarker discovery in cancer
Kai He, Maryam Baniasad, Hyunwoo Kwon, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 23
Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation
Hyun Jung Hwang, Donghee Kang, Jisoo Shin, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Post-Translational Modifications of Proteins Orchestrate All Hallmarks of Cancer
Pathea Bruno, Aneeta Arshad, Maria-Raluca Gogu, et al.
Life (2025) Vol. 15, Iss. 1, pp. 126-126
Open Access | Times Cited: 2
Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy
Xiaoli Hu, Jing Wang, Man Chu, et al.
Molecular Therapy (2021) Vol. 29, Iss. 3, pp. 908-919
Open Access | Times Cited: 96
The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation
Zhiwei Fan, Changyue Wu, Miaomiao Chen, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 3, pp. 1041-1053
Open Access | Times Cited: 62
Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives
Brigida Anna Maiorano, Mauro Francesco Pio Maiorano, Domenica Lorusso, et al.
Cancers (2021) Vol. 13, Iss. 17, pp. 4438-4438
Open Access | Times Cited: 58
Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies
Marc C. Pulanco, Anne Tranberg Madsen, Ankit Tanwar, et al.
Cellular and Molecular Immunology (2023) Vol. 20, Iss. 7, pp. 694-713
Closed Access | Times Cited: 38
In Situ Sprayed Nanovaccine Suppressing Exosomal PD-L1 by Golgi Apparatus Disorganization for Postsurgical Melanoma Immunotherapy
Hao Ye, Kaiyuan Wang, Jian Zhao, et al.
ACS Nano (2023) Vol. 17, Iss. 11, pp. 10637-10650
Closed Access | Times Cited: 36
Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer
Mengdie Wang, Christi Wisniewski, Choua Xiong, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 694
Closed Access | Times Cited: 24
Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD‐L1 in Cancer Therapy
Yazhen Wang, Zhou Yang, Lianyi Yang, et al.
Advanced Science (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 22
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors
Brigida Anna Maiorano, Massimo Di Maïo, Linda Cerbone, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e241215-e241215
Open Access | Times Cited: 9
Glycans as Targets for Drug Delivery in Cancer
Francisca Diniz, Pedro Coelho, Henrique O. Duarte, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 911-911
Open Access | Times Cited: 36
ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma
Tongyuan Qu, Wenshuai Zhang, Chenhui Yan, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 18
Benefits and Pitfalls of a Glycosylation Inhibitor Tunicamycin in the Therapeutic Implication of Cancers
Snigdha Banerjee, Affan A. Ansari, Sunil P. Upadhyay, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 395-395
Open Access | Times Cited: 7
Recent advances and mechanisms of action of PD-L1 degraders as potential therapeutic agents
Feng Zhang, Ruiya Jiang, Shishi Sun, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116267-116267
Closed Access | Times Cited: 6
Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy
Hyung‐Don Kim, Jinho Shin, In Hye Song, et al.
Gastric Cancer (2024) Vol. 27, Iss. 4, pp. 819-826
Closed Access | Times Cited: 6
Dual impacts of serine/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation
Huan Tong, Z. X. Jiang, Linlin Song, et al.
Cell Metabolism (2024)
Open Access | Times Cited: 6
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
Giuseppe Lamberti, Monia Sisi, Elisa Andrini, et al.
Cancers (2020) Vol. 12, Iss. 11, pp. 3129-3129
Open Access | Times Cited: 45
The Role of Glycosylation in Melanoma Progression
Chiara De Vellis, Silvia Pietrobono, Barbara Stecca
Cells (2021) Vol. 10, Iss. 8, pp. 2136-2136
Open Access | Times Cited: 34
Emerging role of PD-L1 modification in cancer immunotherapy.
Xiaoli Hu, Zixia Lin, Zhiwei Wang, et al.
American Journal of Cancer Research (2021) Vol. 11, Iss. 8, pp. 3832-3840
Closed Access | Times Cited: 33
Glycosyltransferases in Cancer: Prognostic Biomarkers of Survival in Patient Cohorts and Impact on Malignancy in Experimental Models
Michela Pucci, Martina Duca, Nadia Malagolini, et al.
Cancers (2022) Vol. 14, Iss. 9, pp. 2128-2128
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top